pharmaceuticals Article Design and Synthesis of Novel Symmetric Fluorene-2,7-Diamine Derivatives as Potent Hepatitis C Virus Inhibitors Mai H. A. Mousa 1, Nermin S. Ahmed 1,*, Kai Schwedtmann 2, Efseveia Frakolaki 3, Niki Vassilaki 3, Grigoris Zoidis 4 , Jan J. Weigand 2 and Ashraf H. Abadi 1,* 1 Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo 11835, Egypt;
[email protected] 2 Faculty of Chemistry and Food Chemistry, Technische Universität Dresden, 01062 Dresden, Germany;
[email protected] (K.S.);
[email protected] (J.J.W.) 3 Molecular Virology Laboratory, Hellenic Pasteur Institute, 11521 Athens, Greece;
[email protected] (E.F.);
[email protected] (N.V.) 4 Department of Pharmacy, Division of Pharmaceutical Chemistry, School of Health Sciences, National and Kapodistrian University of Athens, 15771 Athens, Greece;
[email protected] * Correspondence:
[email protected] (N.S.A.);
[email protected] (A.H.A.); Tel.: +202-27590700 (ext. 3429) (N.S.A.); +202-27590700 (ext. 3400) (A.H.A.); Fax: +202-27581041 (N.S.A. & A.H.A.) Abstract: Hepatitis C virus (HCV) is an international challenge. Since the discovery of NS5A direct-acting antivirals, researchers turned their attention to pursue novel NS5A inhibitors with optimized design and structure. Herein we explore highly potent hepatitis C virus (HCV) NS5A Citation: Mousa, M.H.A.; Ahmed, inhibitors; the novel analogs share a common symmetrical prolinamide 2,7-diaminofluorene scaffold. N.S.; Schwedtmann, K.; Frakolaki, E.; Modification of the 2,7-diaminofluorene backbone included the use of (S)-prolinamide or its isostere Vassilaki, N.; Zoidis, G.; Weigand, J.J.; (S,R)-piperidine-3-caboxamide, both bearing different amino acid residues with terminal carbamate Abadi, A.H.